CRISPR ended 2023 with a bang. In November, the gene editing tool scored its first clinical approval for treating sickle cell anemia and beta-thalassemia in the United Kingdom. These painful blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results